Abstract 3249
Background
Androgen deprivation therapy (ADT) and surveillance are standard options for patients (pts) with biochemically recurrent (non-metastatic, castration sensitive) prostate cancer (BCRpc) after localized therapy. Enzalutamide (enz) extends survival in advanced prostate cancer and is being tested in earlier stages of disease.
Methods
Eligible pts had a PSA between 2.0-20.0 ng/ml, no metastatic disease, normal testosterone (T), and a PSA doubling time of less than 12 months. Treatment for all pts included enz 160 mg daily for 84 days (D) with/without PROSTVAC (recombinant poxvirus PSA vaccine), but no ADT. After an amendment, pts were eligible for a 2nd course of enz after PSA returned to baseline and confirmation of non-metastatic disease. This analysis evaluated all pts for the impact of enz on PSA and T regardless of randomization as findings were similar in each group.
Results
Median age for all pts (n = 36) was 64 years (range: 54-85) with a median baseline PSA of 5.02 (range: 2.02–19.43). The median PSA decline during the first course of enz was >99% (range: 84 - >99). After enz was discontinued, the median time to first PSA rise was 28 D (range:13–182) and median recovery to baseline PSA was 224 D (range:84–924+). 22 of the 36 evaluable pts received a 2ndcourse of enz. Similarly, these patients had a median PSA decline of 99% (range 87->99). After the 2ndcourse of enz, the median time to first PSA rise was 29 D (range:0–83) with a median time to 2nd PSA recovery of 189 D (range:78–400). Enz was well tolerated with no grade 4 or 5 adverse events (AEs). Grade 3 AEs included increased ALT (5%) and decreased ANC (3%). The most common grade 2 AEs included fatigue (18%), dizziness (8%), decreased WBC (8%), and a decreased ALC (8%). T increased above normal limits in 20/36 pts (median Tmax = 834 ng/dl).
Conclusions
Intermittent, short course (84 d) enz without ADT leads to deep and prolonged PSA suppression below baseline in pts with BCRpc, a median of more than 7.5 months beyond treatment period. Pts who received a 2nd 84 D course of enz had similar depth and duration of PSA suppression below baseline (more than 6.5 months after enz treatment). Intermittent enz was well tolerated and warrants further study in BCRpc.
Clinical trial identification
NCT01875250.
Legal entity responsible for the study
National Institutes of Health/National Cancer Institute.
Funding
National Institutes of Health.
Editorial Acknowledgement
None
Disclosure
P. Arlen: Stock, Salary: Precision Biologics. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract